Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

July 07, 2014

Acorda Therapeutics Inc. et al. v. Alkem Laboratories Ltd. et al.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. March 31, 2017

    Key Patents Wiped Out For Acorda's Flagship MS Drug

    A Delaware federal judge on Friday nixed four patents shielding Acorda Therapeutics' multiple sclerosis drug Ampyra, paving the way for generics to hit the market nearly 10 years earlier than expected and jeopardizing nearly $500 million in annual sales.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login